Eradication of nasal carriage of Staphylococcus aureus - Is it cost-effective?

Journal of Hospital Infection

Volumn 40, Issue SUPPL. B, 1998, Pages

  Davey, P ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Eradication; Mupirocin; Nasal carriage; Staphylococcus aureus infections

Indexed keywords

ANTIINFECTIVE AGENT; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM CARRIER; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ERADICATION THERAPY; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HEMODIALYSIS; HOSPITAL COST; HOSPITALIZATION; HUMAN; NOSE; POSTOPERATIVE INFECTION; STAPHYLOCOCCUS AUREUS; THORAX SURGERY; WOUND INFECTION;

EID: 0031787677     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(98)90202-X     Document Type: Conference Paper

References (14)

1. Maynard A. Is it worthwhile reducing hospital infection rates? In: Taylor EW, Ed. Infection in surgical practice. Oxford: Oxford Medical Publications 1992; 119-122.
2. McGowan JEJ. Cost and benefit in control of nosocomial infection: methods for analysis. Rev Infect Dis 1981; 3: 790-797.
3. Jewell M. Cost-containment using an outcome-based best practice model for the management of MRSA. J Chemother 1994; VI: 35-39.
4. McGowan JEJ. Success, failures and costs of implementing standards in the USA-lessons for infection control. J Hosp Infect 1995; 30: 76-87.
5. Mehtar S. Infection control programmes - are they cost-effective? J Hosp Infect 1995; 30: 26-34.
6. Wenzel RP. The economics of nosocomial infections. J Hosp Infect 1995; 31: 79-87.
7. Whynes DK, Walker AR. On approximations in treatment costing. Health Econ 1995; 4: 31-39.
8. VandenBergh MFQ, Kluytmans AJW, van Hout BA et al. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996; 17: 786-792.
9. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513-524.
10. Bloom BS, Fendrick M, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27: 687-694.
11. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-239.
12. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Rodriguez-Lozano I, Moncalian J. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long term results. Am J Kidney Dis 1993; 22: 708-712.
13. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 7: 2403-2408.
14. Davey P, Craig AM and the Mupirocin CAPD trial group. Randomised clinical trial and cost analysis of mupirocin for prevention of exit site infections (ESI) in continuous ambulatory peritoneal dialysis (CAPD). Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, USA, September 15-18 1996.